INOVIQ LTD — Capital/Financing Update 2018

Nov 26, 2018

==> picture [155 x 50] intentionally omitted <==

NON-RENOUNCEABLE ENTITLEMENT OFFER DESPATCH OF OFFER DOCUMENT

Perth, Australia, 26 November 2018: Australian biotechnology company BARD1 Life Sciences Limited (ASX:BD1) is pleased to advise that the Offer Document in connection with its non-renounceable Entitlement Issue and the Entitlement and Acceptance Form were despatched to Eligible Shareholders today.

Any enquiries regarding the Entitlement Offer should be directed to the Company Secretary on +618 93819550.

P Collinson Company Secretary

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian-based biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes BARD1 autoantibody tests in development for early detection of breast, ovarian and lung cancers. Additional diagnostic projects will be evaluated for other cancers. The company also has a cancer vaccine project at research-stage for treatment of cancer. BARD1 is committed to transforming the early detection of cancer to save lives. For more information on BARD1, see www.bard1.com.

BARD1 Life Sciences Limited (ABN 58 009 070 384) Registered Office | Suite B1, Tempo Building, 431 Roberts Road, Subiaco WA 6008, Australia P +618 9381 9550 | F +618 9388 7559 | E info@bard1.com | W www.bard1.com